■ Ophthalmic medical device company Implandata Ophthalmic Products announced that the first patient in its international, multicenter, ARGOS-SC01 clinical study has been successfully implanted with its novel pressure sensor. This first-in-human clinical study is being conducted to validate the suprachoroidally placed Eyemate-SC sensor implant for continual monitoring of IOP.
“The new Implandata sensor is pleasantly small and easy to surgically implant, therefore most patients undergoing glaucoma surgery are likely to be eligible candidates for such a pressure sensor,” said principal investigator Prof. Peter Szurman of the Eye Clinic Sulzbach, Knappschaft Hospital Saar in Sulzbach, Germany. “This breakthrough product enables glaucoma patients for the first time to monitor their own eye pressure at any point in time. I expect that it will improve therapeutic compliance and also significantly reduce the risk of unnecessary visual field loss or even blindness due to glaucoma.”
Implandata has already earned a CE mark for the Eyemate-IO intraocular sensor implant, intended for use in glaucoma patients undergoing cataract surgery. The Eyemate-SC device allows implantation in glaucoma patients not indicated for cataract surgery yet, thus complementing Implandata’s product offering and expanding the indication of use of the Eyemate system.